Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Roberto Mina, Mattia D’Agostino, Chiara Cerrato, Francesca Gay & Antonio Palumbo. (2017) Plasma cell leukemia: update on biology and therapy. Leukemia & Lymphoma 58:7, pages 1538-1547.
Read now
Read now
Mahmoud R Gaballa, Jacob P Laubach, Robert L Schlossman, Katherine Redman, Kimberly Noonan, Constantine S Mitsiades, Irene M Ghobrial, Nikhil Munshi, Kenneth C Anderson & Paul G Richardson. (2012) Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Review of Hematology 5:1, pages 51-68.
Read now
Read now
Michaela Liedtke & Bruno C Medeiros. (2010) Plasma cell leukemia: concepts and management. Expert Review of Hematology 3:5, pages 543-549.
Read now
Read now
Ramón García-Sanz. (2006) Thalidomide in multiple myeloma. Expert Opinion on Pharmacotherapy 7:2, pages 195-213.
Read now
Read now
Jan Styczynski, Krzysztof Czyzewski & Mariusz Wysocki. (2006) Ex vivo activity of thalidomide in childhood acute leukemia. Leukemia & Lymphoma 47:6, pages 1123-1128.
Read now
Read now
Angela Dispenzieri, Martha Q. Lacy, S. Vincent Rajkumar, Susan M. Geyer, Thomas E. Witzig, Rafael Fonseca, John A. Lust, Philip R. Greipp, Robert A. Kyle & Morie A. Gertz. (2003) Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 10:4, pages 257-261.
Read now
Read now
Saad Habib Abdalla & Sarah Mahmoud. (2003) Thalidomide in Relapsed or Refractory Multiple Myeloma: How Much and for How Long?. Leukemia & Lymphoma 44:6, pages 989-991.
Read now
Read now
A.D. Wechalekar, C.I. Chen, D. Sutton, D. Reece, M. Voralia & A.K. Stewart. (2003) Intermediate Dose Thalidomide (200 mg Daily) has Comparable Efficacy and Less Toxicity than Higher Doses in Relapsed Multiple Myeloma. Leukemia & Lymphoma 44:7, pages 1147-1149.
Read now
Read now
S.A. Schey. (2002) Thalidomide in the Management of Multiple Myeloma. Hematology 7:5, pages 291-299.
Read now
Read now
Articles from other publishers (33)
Sehrish Sarwar Baloch, Saqib Raza Khan, Muhammad Tariq, Abdul Wasio, Ayesha Arshad Ali, Mehwish Shahzadi, Munira Moosajee, Shaheena Anwar, Afsheen Raza & Shahab Uddin. (2023) Multiple myeloma and its rare paraneoplastic manifestations simmering under the surface. Pathology - Research and Practice 248, pages 154689.
Crossref
Crossref
Jian Yan, Shiyang Sun, Wenjuan Zhang, Pengyun Li & Zhibing Zheng. (2021) Combined scaffold hopping, molecular screening with dynamic simulation to screen potent CRBN ligands. Journal of Cellular Biochemistry 122:9, pages 1207-1215.
Crossref
Crossref
Christopher Heim, Dimanthi Pliatsika, Farnoush Mousavizadeh, Kerstin Bär, Birte Hernandez Alvarez, Athanassios Giannis & Marcus D. Hartmann. (2019) De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives. Journal of Medicinal Chemistry 62:14, pages 6615-6629.
Crossref
Crossref
Wilson I. Gonsalves & Shaji K. Kumar. 2017. Biology and Management of Unusual Plasma Cell Dyscrasias. Biology and Management of Unusual Plasma Cell Dyscrasias
1
16
.
Pellegrino Musto, Vittorio Simeon, Katia Todoerti & Antonino Neri. (2016) Primary Plasma Cell Leukemia: Identity Card 2016. Current Treatment Options in Oncology 17:4.
Crossref
Crossref
Aurélie Ravinet, Jacques Olivier Bay & Olivier Tournilhac. (2014) La leucémie à plasmocytes. Bulletin du Cancer 101:11, pages 1048-1058.
Crossref
Crossref
Taiga Nishihori, Sarah M. Abu Kar, Rachid Baz, Melissa Alsina, Jean-Luc Harousseau & Mohamed A. Kharfan-Dabaja. (2013) Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 19:8, pages 1144-1151.
Crossref
Crossref
C Fernández de Larrea, R A Kyle, B G M Durie, H Ludwig, S Usmani, D H Vesole, R Hajek, J F San Miguel, O Sezer, P Sonneveld, S K Kumar, A Mahindra, R Comenzo, A Palumbo, A Mazumber, K C Anderson, P G Richardson, A Z Badros, J Caers, M Cavo, X LeLeu, M A Dimopoulos, C S Chim, R Schots, A Noeul, D Fantl, U-H Mellqvist, O Landgren, A Chanan-Khan, P Moreau, R Fonseca, G Merlini, J J Lahuerta, J Bladé, R Z Orlowski & J J Shah. (2012) Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27:4, pages 780-791.
Crossref
Crossref
Niels W. C. J. van de Donk, Henk M. Lokhorst, Kenneth C. Anderson & Paul G. Richardson. (2012) How I treat plasma cell leukemia. Blood 120:12, pages 2376-2389.
Crossref
Crossref
Maria Luisa Martínez-Frías. (2012) Talidomida: 50 años después. Medicina Clínica 139:1, pages 25-32.
Crossref
Crossref
Pellegrino Musto, Livio Pagano, Maria Teresa Petrucci, Fortunato Morabito, Tommaso Caravita, Francesco Di Raimondo, Luca Baldini, Patrizia Tosi, Sara Bringhen, Massimo Offidani, Paola Omede’, Antonino Neri, Fiorella D’Auria, Giovanni Battista Bochicchio, Michele Cavo, Mario Boccadoro & Antonio Palumbo. (2012) Primary plasma cell leukemia in the era of new drugs: Has something changed?. Critical Reviews in Oncology/Hematology 82:2, pages 141-149.
Crossref
Crossref
Flavio Albarracin & Rafael Fonseca. (2011) Plasma cell leukemia. Blood Reviews 25:3, pages 107-112.
Crossref
Crossref
Taimur Sher, Kena C. Miller, George Deeb, Kelvin Lee & Asher Chanan-Khan. (2010) Plasma cell leukaemia and other aggressive plasma cell malignancies. British Journal of Haematology 150:4, pages 418-427.
Crossref
Crossref
Hirokazu Murakami, Kazuyuki Shimizu, Morio Sawamura, Kenshi Suzuki, Isamu Sugiura, Hiroshi Kosugi, Chihiro Shimazaki, Masafumi Taniwaki, Masahiro Abe & Toshiyuki Takagi. (2009) Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. International Journal of Hematology 89:5, pages 636-641.
Crossref
Crossref
Tomoko Kodama, Masahiro Abe, Shinsuke Iida, Shuji Ozaki, Akira Sakai, Morio Sawamura, Chihiro Shimazaki, Akira Miyata, Toshio Wakayama & Hirokazu Murakami. (2009) A Pharmacokinetic Study Evaluating the Relationship Between Treatment Efficacy and Incidence of Adverse Events with Thalidomide Plasma Concentrations in Patients with Refractory Multiple Myeloma. Clinical Lymphoma and Myeloma 9:2, pages 154-159.
Crossref
Crossref
Victor H. Jimenez-Zepeda & Virginia J. Dominguez-Martinez. (2009) Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. International Journal of Hematology 89:3, pages 259-268.
Crossref
Crossref
Pellegrino Musto, Giuseppe Pietrantuono, Roberto Guariglia, Oreste Villani, Maria Carmen Martorelli, Fiorella D’Auria, Antonia Zonno & Rosa Lerose. (2008) Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leukemia Research 32:10, pages 1637-1638.
Crossref
Crossref
Ashraf Badros. 2009. Myeloma Therapy. Myeloma Therapy
205
227
.
Stelvio Ballanti, Elena Mastrodicasa, Niccolò Bolli, Flavia Lotti, Ilaria Capolsini, Laura Berchicci, Carla Merigiola, Giampiero Giordano & Antonio Tabilio. (2007) Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nature Clinical Practice Oncology 4:12, pages 722-725.
Crossref
Crossref
Hirokazu Murakami, Hiroshi Handa, Masahiro Abe, Sinsuke Iida, Akihiro Ishii, Takayuki Ishikawa, Tadao Ishida, Masatsugu Oota, Shuji Ozaki, Masaaki Kosaka, Akira Sakai, Morio Sawamura, Chihiro Shimazaki, Kazuyuki Shimizu, Toshiyuki Takagi, Hiroyuki Hata, Takashi Fukuhara, Hiroshi Fujii, Akira Miyata, Toshio Wakayama & Kiyoshi Takatsuki. (2007) Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. European Journal of Haematology 79:3, pages 234-239.
Crossref
Crossref
Pellegrino Musto, Fausto Rossini, Francesca Gay, Vincenzo Pitini, Tommasina Guglielmelli, Giovanni D'Arena, Felicetto Ferrara, Nunzio Filardi, Roberto Guariglia & Antonio Palumbo. (2007) Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 109:11, pages 2285-2290.
Crossref
Crossref
Linda Mileshkin, Richard Stark, Bruce Day, John F. Seymour, Jerome B. Zeldis & H. Miles Prince. (2006) Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring. Journal of Clinical Oncology 24:27, pages 4507-4514.
Crossref
Crossref
Víctor Hugo Jiménez-Zepeda & Virginia Jeanet Domínguez. (2006) Plasma cell leukemia: a rare condition. Annals of Hematology 85:4, pages 263-267.
Crossref
Crossref
Axel Glasmacher, Corinna Hahn, Florian Hoffmann, Ralph Naumann, Hartmut Goldschmidt, Marie Lilienfeld-Toal, Katjana Orlopp, Ingo Schmidt-Wolf & Marcus Gorschluter. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British Journal of Haematology 132:5, pages 584-593.
Crossref
Crossref
Klaus Podar, Teru Hideshima, Yu-Tzu Tai, Paul G Richardson, Dharminder Chauhan & Kenneth C Anderson. (2006) Emerging Therapies for Multiple Myeloma. American Journal of Cancer 5:3, pages 141-153.
Crossref
Crossref
Heinz Albert Dürk. (2006) Maintenance Therapy for Multiple Myeloma with Particular Emphasis on Thalidomide. Oncology Research and Treatment 29:12, pages 582-590.
Crossref
Crossref
Benedetto Bruno, Marcello Rotta, Luisa Giaccone, Massimo Massaia, Alessandra Bertola, Antonio Palumbo & Mario Boccadoro. (2004) New drugs for treatment of multiple myeloma. The Lancet Oncology 5:7, pages 430-442.
Crossref
Crossref
Carla S. Wilson. 2004. Hematopathology in Oncology. Hematopathology in Oncology
113
144
.
S.A. Schey, J. Cavenagh, R. Johnson, J.A. Child, H. Oakervee & R.W. Jones. (2003) An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Research 27:10, pages 909-914.
Crossref
Crossref
Rossella Manfredini, Elena Tenedini, Michela Siena, Enrico Tagliafico, Monica Montanari, Alexis Grande, Tommaso Zanocco-Marani, Cristina Poligani, Roberta Zini, Claudia Gemelli, Anna Bergamaschi, Tatiana Vignudelli, Francesca De Rienzo, Pier Giuseppe De Benedetti, Maria Cristina Menziani & Sergio Ferrari. (2003) Development of an IL-6 antagonist peptide that induces apoptosis in 7TD1 cells. Peptides 24:8, pages 1207-1220.
Crossref
Crossref
David C. Seldin, Elie B. Choufani, Laura M. Dember, Janice F. Wiesman, John L. Berk, Rodney H. Falk, Carl O'Hara, Salli Fennessey, Kathleen T. Finn, Daniel G. Wright, Martha Skinner & Vaishali Sanchorawala. (2003) Tolerability and Efficacy of Thalidomide for the Treatment of Patients with Light Chain–Associated (AL) Amyloidosis. Clinical Lymphoma 3:4, pages 241-246.
Crossref
Crossref
Peter H. Wiernik. 2003.
365
397
.
. (2002) Current Awareness in Hematological Oncology. Hematological Oncology 20:4, pages 189-196.
Crossref
Crossref